Canadian cardiovascular harmonized national guidelines endeavour (C-CHANGE): 2014 update

TY - JOUR

T1 - Canadian cardiovascular harmonized national guidelines endeavour (C-CHANGE)

T2 - 2014 update

AU - for the C-CHANGE Initiative

AU - Tobe, Sheldon W.

AU - Stone, James A.

AU - Walker, Kimberly M.

AU - Anderson, Todd

AU - Bhattacharyya, Onil

AU - Cheng, Alice Y.Y.

AU - Gregoire, Jean

AU - Gubitz, Gord

AU - L'Abbe, Mary

AU - Lau, David C.W.

AU - Leiter, Lawrence A.

AU - Oh, Paul

AU - Padwal, Raj

AU - Poirier, Luc

AU - Selby, Peter

AU - Tremblay, Mark

AU - Ward, Richard A.

AU - Hua, Diane

AU - Liu, Peter P.

AU - Brouwers, Melissa

AU - Campbell, Norman R.C.

AU - Dannenbaum, David

AU - Dawes, Martin

AU - Drouin, Denis

AU - Feldman, Ross

AU - Genest, Jacques

AU - Goluboff, Steven

AU - Grover, Steven

AU - Hickey, John

AU - Hutchinson, Tim

AU - Kaczorowski, Janusz

AU - Keshavjee, Karim

AU - Kingsbury, Kori

AU - Mann, Karen

AU - Pipe, Andrew

AU - Sit, Christina

AU - Stern, Sol

AU - Tremblay, Guy

AU - Tu, Karen

AU - Warburton, Darren

AU - Woo, Vincent

AU - Yeung, George

N1 - Funding Information: Funding: Funding for the development of the 2014 C-CHANGE guideline was provided by the Ontario Ministry of Health and Long-term Care. The C-CHANGE implementation activities were funded by the Public Health Agency of Canada (no. 6464-15-201-8041132) and the Ontario Ministry of Health and Long-term Care (grant no. 06668 and 0669). The funders did not have a direct influence on the process, the contents of the recommendations or the preparation of the manuscript. Funding Information: Competing interests: Sheldon Tobe has received research funding from Eli Lilly and Company, AstraZeneca, AbbVie and Bayer. James Stone has received funding from Amgen, Forest Laboratories, Merck and Sanofi. Todd Anderson declares research study involvement with Merck and Amgen. Onil Bhattacharyya has received funding from GlaxoSmithKline, Merck, Merck Serono and Novartis. Alice Cheng declares personal fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Merck, Novo Nordisk, Sanofi, Servier, Valeant Pharmaceuticals International, Abbott and Takeda Pharmaceutical Company. Gord Gubitz has received funds from Pfizer–Bristol-Myers Squibb, Bayer and Boehringer Ingelheim, and is a member of the steering committee for the Heart and Stroke Foundation of Canada Stroke Best Practices. David Lau declares receiving funds from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Janssen, Merck, Novo Nordisk, Roche, Sanofi and Valeant Pharmaceuticals International. Lawrence Leiter declares grants or personal fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Roche, Sanofi, Servier, Takeda Pharmaceutical Company and Amgen. Raj Padwal has received funds from Forest Laboratories, Medtronic, Novo Nordisk, CVRx, Valencia, Abbott, Servier and Merck. Peter Selby has received funds from Pfizer and AbbVie. No competing interests were declared by Kimberly Walker, Onil Bhattacharyya, Jean Gregoire, Gord Gubitz, Mary L'Abbé, Paul Oh, Luc Poirier, Mark Tremblay, Richard Ward and Diane Hua.

PY - 2014/11/18

Y1 - 2014/11/18

UR - http://www.scopus.com/inward/record.url?scp=84958716829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958716829&partnerID=8YFLogxK

U2 - 10.1503/cmaj.140387

DO - 10.1503/cmaj.140387

M3 - Article

C2 - 25332362

AN - SCOPUS:84958716829

SN - 0820-3946

VL - 186

SP - 1299

EP - 1305

JO - CMAJ

JF - CMAJ

IS - 17

ER -